Selected research
Market Structure
Global Recombinant Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Recombinant Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Recombinant Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Recombinant Vaccines include Johnson & Johnson, Novartis AG, Merck & Co., Inc, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AstraZeneca Plc., Serum Institute of India Pvt. Ltd and Sanofi S A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Recombinant Vaccines market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Recombinant Vaccines and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Recombinant Vaccines revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Recombinant Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.
Recombinant Vaccines Segment by Company
Johnson & Johnson
Novartis AG
Merck & Co., Inc
Pfizer Inc.
GlaxoSmithKline Plc.
Bayer AG
AstraZeneca Plc.
Serum Institute of India Pvt. Ltd
Sanofi S A.
Protein Science Corporation
Novavax, Inc
Green Cross Corporation
Emergent BioSolutions Inc
Dynavax Technologies Corporation
Bharat Biotech
Recombinant Vaccines Segment by Type
Vector Recombinant Vaccines
Subunit Recombinant Vaccines
Attenuated Recombinant Vaccines
Recombinant Vaccines Segment by Application
Recombinant Human Vaccines
Animal Recombinant Vaccines
Recombinant Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Recombinant Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Vaccines industry.
Chapter 3: Detailed analysis of Recombinant Vaccines companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Vaccinesrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vector Recombinant Vaccines
- Subunit Recombinant Vaccines
- Attenuated Recombinant Vaccines
Applications
- Recombinant Human Vaccines
- Animal Recombinant Vaccines
Companies covered
- Johnson & Johnson
- Novartis AG
- Merck & Co., Inc
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Bayer AG
- AstraZeneca Plc.
- Serum Institute of India Pvt. Ltd
- Sanofi S A.
- Protein Science Corporation
- Novavax, Inc
- Green Cross Corporation
- Emergent BioSolutions Inc
- Dynavax Technologies Corporation
- Bharat Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Recombinant Vaccines Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Vector Recombinant Vaccines
- 1.2.3 Subunit Recombinant Vaccines
- 1.2.4 Attenuated Recombinant Vaccines
- 1.3 Market Analysis by Application
- 1.3.1 Global Recombinant Vaccines Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Recombinant Human Vaccines
- 1.3.3 Animal Recombinant Vaccines
- 1.4 Global Market Growth Prospects
- 1.5 Global Recombinant Vaccines Growth Trends by Region
- 1.5.1 Global Recombinant Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Recombinant Vaccines Market Size by Region (2021-2026)
- 1.5.3 Recombinant Vaccines Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Recombinant Vaccines Market Dynamics
- 2.1 Recombinant Vaccines Industry Trends
- 2.2 Recombinant Vaccines Industry Drivers
- 2.3 Recombinant Vaccines Industry Opportunities and Challenges
- 2.4 Recombinant Vaccines Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Recombinant Vaccines Revenue by Company (2021-2026)
- 3.2 Global Recombinant Vaccines Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Recombinant Vaccines Key Company Head office and Area Served
- 3.4 Global Recombinant Vaccines Company, Product Type & Application
- 3.5 Global Recombinant Vaccines Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Recombinant Vaccines Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Recombinant Vaccines Players Market Share by Revenue in 2025
- 3.6.3 2025 Recombinant Vaccines Tier 1, Tier 2, and Tier 3
4 Recombinant Vaccines Market by Type
- 4.1 Global Recombinant Vaccines Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Recombinant Vaccines Market Size by Type (2021-2032)
- 4.3 Global Recombinant Vaccines Market Size Share by Type (2021-2032)
5 Recombinant Vaccines Market by Application
- 5.1 Global Recombinant Vaccines Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Recombinant Vaccines Market Size by Application (2021-2032)
- 5.3 Global Recombinant Vaccines Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Johnson & Johnson
- 6.1.1 Johnson & Johnson Company Information
- 6.1.2 Johnson & Johnson Business Overview
- 6.1.3 Johnson & Johnson Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Johnson & Johnson Recombinant Vaccines Product Portfolio
- 6.1.5 Johnson & Johnson Recent Developments
- 6.2 Novartis AG
- 6.2.1 Novartis AG Company Information
- 6.2.2 Novartis AG Business Overview
- 6.2.3 Novartis AG Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Novartis AG Recombinant Vaccines Product Portfolio
- 6.2.5 Novartis AG Recent Developments
- 6.3 Merck & Co., Inc
- 6.3.1 Merck & Co., Inc Company Information
- 6.3.2 Merck & Co., Inc Business Overview
- 6.3.3 Merck & Co., Inc Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Merck & Co., Inc Recombinant Vaccines Product Portfolio
- 6.3.5 Merck & Co., Inc Recent Developments
- 6.4 Pfizer Inc.
- 6.4.1 Pfizer Inc. Company Information
- 6.4.2 Pfizer Inc. Business Overview
- 6.4.3 Pfizer Inc. Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Pfizer Inc. Recombinant Vaccines Product Portfolio
- 6.4.5 Pfizer Inc. Recent Developments
- 6.5 GlaxoSmithKline Plc.
- 6.5.1 GlaxoSmithKline Plc. Company Information
- 6.5.2 GlaxoSmithKline Plc. Business Overview
- 6.5.3 GlaxoSmithKline Plc. Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 GlaxoSmithKline Plc. Recombinant Vaccines Product Portfolio
- 6.5.5 GlaxoSmithKline Plc. Recent Developments
- 6.6 Bayer AG
- 6.6.1 Bayer AG Company Information
- 6.6.2 Bayer AG Business Overview
- 6.6.3 Bayer AG Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Bayer AG Recombinant Vaccines Product Portfolio
- 6.6.5 Bayer AG Recent Developments
- 6.7 AstraZeneca Plc.
- 6.7.1 AstraZeneca Plc. Company Information
- 6.7.2 AstraZeneca Plc. Business Overview
- 6.7.3 AstraZeneca Plc. Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 AstraZeneca Plc. Recombinant Vaccines Product Portfolio
- 6.7.5 AstraZeneca Plc. Recent Developments
- 6.8 Serum Institute of India Pvt. Ltd
- 6.8.1 Serum Institute of India Pvt. Ltd Company Information
- 6.8.2 Serum Institute of India Pvt. Ltd Business Overview
- 6.8.3 Serum Institute of India Pvt. Ltd Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Serum Institute of India Pvt. Ltd Recombinant Vaccines Product Portfolio
- 6.8.5 Serum Institute of India Pvt. Ltd Recent Developments
- 6.9 Sanofi S A.
- 6.9.1 Sanofi S A. Company Information
- 6.9.2 Sanofi S A. Business Overview
- 6.9.3 Sanofi S A. Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Sanofi S A. Recombinant Vaccines Product Portfolio
- 6.9.5 Sanofi S A. Recent Developments
- 6.10 Protein Science Corporation
- 6.10.1 Protein Science Corporation Company Information
- 6.10.2 Protein Science Corporation Business Overview
- 6.10.3 Protein Science Corporation Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Protein Science Corporation Recombinant Vaccines Product Portfolio
- 6.10.5 Protein Science Corporation Recent Developments
- 6.11 Novavax, Inc
- 6.11.1 Novavax, Inc Company Information
- 6.11.2 Novavax, Inc Business Overview
- 6.11.3 Novavax, Inc Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Novavax, Inc Recombinant Vaccines Product Portfolio
- 6.11.5 Novavax, Inc Recent Developments
- 6.12 Green Cross Corporation
- 6.12.1 Green Cross Corporation Company Information
- 6.12.2 Green Cross Corporation Business Overview
- 6.12.3 Green Cross Corporation Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Green Cross Corporation Recombinant Vaccines Product Portfolio
- 6.12.5 Green Cross Corporation Recent Developments
- 6.13 Emergent BioSolutions Inc
- 6.13.1 Emergent BioSolutions Inc Company Information
- 6.13.2 Emergent BioSolutions Inc Business Overview
- 6.13.3 Emergent BioSolutions Inc Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Emergent BioSolutions Inc Recombinant Vaccines Product Portfolio
- 6.13.5 Emergent BioSolutions Inc Recent Developments
- 6.14 Dynavax Technologies Corporation
- 6.14.1 Dynavax Technologies Corporation Company Information
- 6.14.2 Dynavax Technologies Corporation Business Overview
- 6.14.3 Dynavax Technologies Corporation Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Dynavax Technologies Corporation Recombinant Vaccines Product Portfolio
- 6.14.5 Dynavax Technologies Corporation Recent Developments
- 6.15 Bharat Biotech
- 6.15.1 Bharat Biotech Company Information
- 6.15.2 Bharat Biotech Business Overview
- 6.15.3 Bharat Biotech Recombinant Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Bharat Biotech Recombinant Vaccines Product Portfolio
- 6.15.5 Bharat Biotech Recent Developments
7 North America
- 7.1 North America Recombinant Vaccines Market Size (2021-2032)
- 7.2 North America Recombinant Vaccines Market Size by Type
- 7.2.1 North America Recombinant Vaccines Market Size by Type (2021-2026)
- 7.2.2 North America Recombinant Vaccines Market Size by Type (2027-2032)
- 7.2.3 North America Recombinant Vaccines Market Share by Type (2021-2032)
- 7.3 North America Recombinant Vaccines Market Size by Application
- 7.3.1 North America Recombinant Vaccines Market Size by Application (2021-2026)
- 7.3.2 North America Recombinant Vaccines Market Size by Application (2027-2032)
- 7.3.3 North America Recombinant Vaccines Market Share by Application (2021-2032)
- 7.4 North America Recombinant Vaccines Market Size by Country
- 7.4.1 North America Recombinant Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Recombinant Vaccines Market Size by Country (2021-2026)
- 7.4.3 North America Recombinant Vaccines Market Size by Country (2027-2032)
- 7.4.4 North America Recombinant Vaccines Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Recombinant Vaccines Market Size (2021-2032)
- 8.2 Europe Recombinant Vaccines Market Size by Type
- 8.2.1 Europe Recombinant Vaccines Market Size by Type (2021-2026)
- 8.2.2 Europe Recombinant Vaccines Market Size by Type (2027-2032)
- 8.2.3 Europe Recombinant Vaccines Market Share by Type (2021-2032)
- 8.3 Europe Recombinant Vaccines Market Size by Application
- 8.3.1 Europe Recombinant Vaccines Market Size by Application (2021-2026)
- 8.3.2 Europe Recombinant Vaccines Market Size by Application (2027-2032)
- 8.3.3 Europe Recombinant Vaccines Market Share by Application (2021-2032)
- 8.4 Europe Recombinant Vaccines Market Size by Country
- 8.4.1 Europe Recombinant Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Recombinant Vaccines Market Size by Country (2021-2026)
- 8.4.3 Europe Recombinant Vaccines Market Size by Country (2027-2032)
- 8.4.4 Europe Recombinant Vaccines Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Recombinant Vaccines Market Size (2021-2032)
- 9.2 China Recombinant Vaccines Market Size by Type
- 9.2.1 China Recombinant Vaccines Market Size by Type (2021-2026)
- 9.2.2 China Recombinant Vaccines Market Size by Type (2027-2032)
- 9.2.3 China Recombinant Vaccines Market Share by Type (2021-2032)
- 9.3 China Recombinant Vaccines Market Size by Application
- 9.3.1 China Recombinant Vaccines Market Size by Application (2021-2026)
- 9.3.2 China Recombinant Vaccines Market Size by Application (2027-2032)
- 9.3.3 China Recombinant Vaccines Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Recombinant Vaccines Market Size (2021-2032)
- 10.2 Asia Recombinant Vaccines Market Size by Type
- 10.2.1 Asia Recombinant Vaccines Market Size by Type (2021-2026)
- 10.2.2 Asia Recombinant Vaccines Market Size by Type (2027-2032)
- 10.2.3 Asia Recombinant Vaccines Market Share by Type (2021-2032)
- 10.3 Asia Recombinant Vaccines Market Size by Application
- 10.3.1 Asia Recombinant Vaccines Market Size by Application (2021-2026)
- 10.3.2 Asia Recombinant Vaccines Market Size by Application (2027-2032)
- 10.3.3 Asia Recombinant Vaccines Market Share by Application (2021-2032)
- 10.4 Asia Recombinant Vaccines Market Size by Country
- 10.4.1 Asia Recombinant Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Recombinant Vaccines Market Size by Country (2021-2026)
- 10.4.3 Asia Recombinant Vaccines Market Size by Country (2027-2032)
- 10.4.4 Asia Recombinant Vaccines Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Recombinant Vaccines Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Recombinant Vaccines Market Size by Type
- 11.2.1 South America, Middle East & Africa Recombinant Vaccines Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Recombinant Vaccines Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Recombinant Vaccines Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Recombinant Vaccines Market Size by Application
- 11.3.1 South America, Middle East & Africa Recombinant Vaccines Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Recombinant Vaccines Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Recombinant Vaccines Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Recombinant Vaccines Market Size by Country
- 11.4.1 South America, Middle East & Africa Recombinant Vaccines Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Recombinant Vaccines Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Recombinant Vaccines Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Recombinant Vaccines Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst